In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Milestone Pharmaceuticals (MIST – Research Report), with ...
After calling for a major discount for Pfizer’s popular transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis, a U.S.
TD Cowen raised the firm’s price target on Alnylam (ALNY) to $371 from $282 and keeps a Buy rating on the shares. The firm updated its ...